Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Tumors were resected from mice 10 days after orthotopic inoculation of 4T1-Luc2 cells, and hydrogels loaded with the following payloads were evaluated: anti–PD-1, anti-CTLA-4, IL-15sa, lenalidomide, celecoxib, STING-RR, or R848. Mice that did not receive a hydrogel were examined as a negative control. (A) IVIS imaging of 4T1-Luc2 cells is shown for all groups described and illustrates tumor burden.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Celecoxib purchased from Selleck.

    Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

  • Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

    Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

  • Oncol Lett, 2018, 16(1):317-325. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MkHISpVv[3Srb36gRZN{[Xl? M{S4fFAvOS1|MDFOwG0> NEjGT2k1QCCq MoKxbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> MlfONlY2OTNzN{K=
H460 M2KxUGZ2dmO2aX;uJGF{e2G7 NUCzcXpqOC5zLUOwJO69VQ>? MlnyOFghcA>? M17Mb4lv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt M3\PNFI3PTF|MUey
HKESC-2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmyNOKh|ryP Ml;BOFjDqGkEoB?= MXnzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> MVWyOlQ4PDZ7Mx?=
CaES-17 M3mzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfIbpdqOjEEoN88US=> NH;0dnk1QMLiaNMg MULzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> Mn3LNlY1PzR4OUO=
HKESC-2 MXrBdI9xfG:|aYOgRZN{[Xl? NUfScGVyOjEEoN88US=> MYK0POKhcMLi NGLxPFNz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ NGjiSGYzPjR5NE[5Ny=>
CaES-17 Mme1RZBweHSxc3nzJGF{e2G7 NG\EclYzOMLizszN M{LxN|Q5yqCqwrC= MkTRdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MnHjNlY1PzR4OUO=
A549 NVfzVI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XnPVUuOTZyIN88US=> MVi0POKhcMLi NUfnO2dxTE2VTx?= MYjJR|UxRTF4Mz60JO69VQ>? M2LqflI3PDZ2NkSz
HCC827 Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfpNJg2NTF4MDFOwG0> NFXwWpU1QMLiaNMg Mn;FSG1UVw>? M1HsVGlEPTB;NkmuNkDPxE1? NEjLToszPjR4NE[0Ny=>
A549 M33BZmFxd3C2b4Ppd{BCe3OjeR?= MnLmPFAhyrWP NHHiV3E1QMLiaNMg NFzHSlhFVVOR MWTpcoR2[2W|IHHwc5B1d3Orcx?= NGj0XGEzPjR4NE[0Ny=>
HCC827 NYHWZVhiSXCxcITvd4l{KEG|c3H5 NEXHO5M5OCEEtV2= M1LkcVQ5yqCqwrC= MYLEUXNQ NFvHSYVqdmS3Y3XzJIFxd3C2b4Ppdy=> MnfjNlY1PjR4NEO=
SGC-7901/DDP MkHCSpVv[3Srb36gRZN{[Xl? MnjUNVDDqML3TR?= MkDBNlQhcA>? NFSx[VZqdmirYnn0d{BkgWOub3;4fYdmdmG|ZT2yJIFv\CCSLXfsfYNweHKxdHXpckBmgHC{ZYPzbY9v MV2yOlQxPzZ3Mx?=
SGC-7901  NU\3UYhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqyOOKhcMLi M1\5bmlEPTB;MUG1MlA5KM7:TR?= NYnzNZR6OjZ2MEe2OVM>
SGC-7901/DDP Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jWfFI1yqCqwrC= MX;JR|UxRTN3LkS1JO69VQ>? NE\OdWYzPjRyN{[1Ny=>
SGC-7901/DDP M2fwcGFxd3C2b4Ppd{BCe3OjeR?= NILiNIoyOMLiwsXN MUeyOEBp MWHpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKHerdHigZ4l{eGyjdHnu NUnncmF3OjZ2MEe2OVM>
SGC-7901/DDP NI\abI1HfW6ldHnvckBCe3OjeR?= MWOxNOKhyrWP M3;ZXlI1KGh? NEPROIdqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBRNWeueXPvdJJwfGWrbjD0bJJwfWeqIHLsc4NscW6pIFXQNkwh[W6mIHnuZYN1cX[jdHnu[{BRU0FiYX7kJGNTTUMEoB?= M1zFb|I3PDB5NkWz
SGC-7901/DDP MV\GeY5kfGmxbjDBd5NigQ>? NH3GPFMyOMLiwsXN NF\Yd2ozPCCq M1;vOoNifXOnczDhJI1iemunZDDk[YNz\WG|ZTDpckB1cGVibHX2[Ywhd2ZiQnPsMVIheHKxdHXpci=> NILrfXgzPjRyN{[1Ny=>
H357 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\RW5diPy53L{GwJO69VQ>? MXK0PEBp NX7yUnB2TE2VTx?= NInZc4dqdmirYnn0d{Bk\WyuIHfyc5d1cMLiY3;tZolv\WRid3n0bEBU[WK3dH;jcIF5 M2DXVlI3ODB7OEe0
TAF MkS2SpVv[3Srb36gRZN{[Xl? MnjXNVDDqML3TR?= NGjaRnM4KGR? M2jJ[4Fn\mWldIOgWGFHeyCjZHjld4l3\SCycn;w[ZJ1cWW| NV;OeXM2OjV7OEexNlc>
TAF NWDy[4NvTnWwY4Tpc44hSXO|YYm= MVixNOKhyrWP M2HrRlMxNTF{MDDtbY4> M37JTZBwd3KueTDh[oZm[3S|IHTBb5QheGixc4Doc5J6dGG2aX;uJINwdnOncYXlcpQhfG9iRVfGJJNq\26jbHnu[y=> NXXY[pFZOjV7OEexNlc>
TAF MoHmSpVv[3Srb36gRZN{[Xl? M2mycVExyqEEtV2= NInnWXU1QCCq M1:3Z4lv[3KnYYPld{BGT0[UIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NVzUTIl1OjV7OEexNlc>
PANC-1 NVHDemRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2yNE83OC9zMECg{txO NF\6c4szPC92OD:3NkBp NFrTTYpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NUPOeWhFOjV7N{OwOlI>
PANC-1 NYrYUot2TnWwY4Tpc44hSXO|YYm= M4nzU|IxNzZyL{GwNEDPxE1? MV:yOEBp NEna[phifHSnboXheJMh[2WubDDpcpZie2mxbjDhcoQhdWmpcnH0bY9vKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MnXyNlU6PzNyNkK=
HeLa  MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HFeVIxyqEQvF5CpC=> MWKyOOKhcA>? NXzYSYRW\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= NXG3XlNvOjV5N{C0NlM>
SACC-83 NETDfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrmfpJHOjEEoN88UeKh M{nLWFI1yqCq NHjKZoNmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= M3j6VlI2PzdyNEKz
HeLa  NXvYOpRXSXCxcITvd4l{KEG|c3H5 NF3lZY0zOMLizszNxsA> NWPFRmVOOjUEoHi= MlzP[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> NVy3eG9GOjV5N{C0NlM>
SACC-83 NWL5WY5pSXCxcITvd4l{KEG|c3H5 MWCyNOKh|ryPwrC= Mn;lNlTDqGh? M13LRYVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> NGTz[G4zPTd5MESyNy=>
HeLa  NETzZWJHfW6ldHnvckBCe3OjeR?= Mn[2NlAwPDBxOECg{txO MUmyOOKhcA>? MUP1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NFLHUYozPTd5MESyNy=>
SACC-83 MUnGeY5kfGmxbjDBd5NigQ>? NHzOdmwzOC92MD:4NEDPxE1? MYWyOOKhcA>? MX\1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NH3nVY0zPTd5MESyNy=>
HLCZ01 MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HuSVDjiJN4MNMgxtVO Mk\KOFghcA>? NGPFUVhFVVOR M2j6b4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NFS4cWszPTd{NEi5PS=>
HLCZ01 M3rwbWZ2dmO2aX;uJGF{e2G7 MUG0NOKh|ryP M{jRXVI1KGh? NIjRbmRFVVOR MVvpcoNz\WG|ZYOgZYNkfW23bHH0bY9vKG:oIFewM2cyNXCqYYPlJINmdGy|IHPvcYJqdmWmIIfpeIghUU[QLd8x MX[yOVczPDh7OR?=
HLCZ01 NV7NenhUSXCxcITvd4l{KEG|c3H5 MnXJOFDDqM7:TR?= M3PNbFI1KGh? M1znT2ROW09? MnPU[Y5p[W6lZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiSV\OMe6y MYmyOVczPDh7OR?=
HLCZ01 M2fvdmZ2dmO2aX;uJGF{e2G7 M2\MflQxyqEQvF2= Mn7pNlQhcA>? NUf6UHY2TE2VTx?= MYfpcoNz\WG|ZYOgWHJCUUxiZYjwdoV{e2mxbjDjc41jcW6nZDD3bZRpKEmwdHXy[oVzd25vzsG= MkmyNlU4OjR6OUm=
MGC803 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DoVFAuPjBizszN MX63NkBp MoHLTWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2= MVuyOVcxOTN5OB?=
SGC7901 M{\zVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETaPHMxNTZyIN88US=> Mn3NO|IhcA>? M3n2RWlEPTB;NEOuOVPjiIoEsfMAjVUvOTJizszN MkT0NlU4ODF|N{i=
MGC803 M{frWGZ2dmO2aX;uJGF{e2G7 M4jpOlQxyqEQvF2= M3ricFgwOTZxMkSgbC=> MYL1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36= M4HVelI2PzBzM{e4
SGC7901 Mlf1SpVv[3Srb36gRZN{[Xl? NVXq[Ip4PDEEoN88US=> MYe4M|E3NzJ2IHi= M{H4bpVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> MXiyOVcxOTN5OB?=
MCF-7  NGjid5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f2bVEwOTBizszN NFmxOGc4OiCq NUfLOow5TE2VTx?= M1LIR4VvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w MmDxNlU3Pjd3MUC=
MDA-MB-231  NX3lc4h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuxM|ExKM7:TR?= NIO1RmI4OiCq MV;EUXNQ NGjjRYdmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= NETSfZQzPTZ4N{WxNC=>
MDA-MB-231 NYf3WZpLTnWwY4Tpc44hSXO|YYm= MYCwMVQxKML3TR?= NULZd5psPC1{NDDo Ml[xbY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Ml7INlU2QDd|Mkm=
MCF-7 NICwRlFHfW6ldHnvckBCe3OjeR?= MkL2NE01OCEEtV2= M1Swe|QuOjRiaB?= MmDH[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? NFrVWnYzPTV6N{OyPS=>
MCF7-MX  NYXCOpczTnWwY4Tpc44hSXO|YYm= NF3GW3IxNTRyINM1US=> NYG5TFFlPC1{NDDo M1zmeoVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? M4PGdFI2PTh5M{K5
MDA-MB-231 NVLvUllETnWwY4Tpc44hSXO|YYm= Mn3ENE01OCEEtV2= MWW0MVI1KGh? Ml\1d5RqdXWuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBCSkOJMjD1dEB1dyB2LkK3JJRqdWW|IITvJINwdnS{b3ygcIV3\WxiYomgNVIhcMLi NFzLZ3EzPTV6N{OyPS=>
A2780 MWDGeY5kfGmxbjDBd5NigQ>? NEXrbGw2NzFyL{G1JO69VQ>? Mn;BOFghcA>? MWPk[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVKyOVQzPDh7OB?=
SKOV3  NF7uZlhHfW6ldHnvckBCe3OjeR?= MnjQOU8yOC9zNTFOwG0> MmjuOFghcA>? NFW4Vodl\WO{ZXHz[ZMhS2:6LUKg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mni2NlU1OjR6OUi=
A2780 NVHUbYZSTnWwY4Tpc44hSXO|YYm= MVu1M|ExNzF3IN88US=> MXG0PEBp M{PBTIVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? MlXFNlU1OjR6OUi=
SKOV3  NVLYfJVDTnWwY4Tpc44hSXO|YYm= MYe1M|ExNzF3IN88US=> NEOzOIM1QCCq M3TaN4Vt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? NUTX[Y1GOjV2MkS4PVg>
A2780 MXfGeY5kfGmxbjDBd5NigQ>? NF3jPI82NzFyL{G1JO69VQ>? MofQOFghcA>? NFSxVm5l\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= NH;kN|gzPTR{NEi5PC=>
SKOV3  NWXl[YFlTnWwY4Tpc44hSXO|YYm= M3zrblUwOTBxMUWg{txO MW[0PEBp M3jDZ4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= Mlj4NlU1OjR6OUi=
A2780 NITEcZdHfW6ldHnvckBCe3OjeR?= M13nXFUwOTBxMUWg{txO MnHDNUBp NXHUcWJmcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHBvQVvUJIFv\CCyLVXST{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NEnS[FQzPTR{NEi5PC=>
SKOV3  NYT5UW06TnWwY4Tpc44hSXO|YYm= NWXKNHBZPS9zMD:xOUDPxE1? NH76[2MyKGh? MXrpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGnlWYwzPTR{NEi5PC=>
HCT-15 NGrWUZpHfW6ldHnvckBCe3OjeR?= MWCxNE02OCEQvF2= M3rYO|YuOzZiaB?= NILCXHZqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy MmTDNlUzOThyMki=
HT-29  NXfWR3JXTnWwY4Tpc44hSXO|YYm= NXvGOYFtOTBvNUCg{txO NG[1SZQ3NTN4IHi= NULxc4VicW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NHj4ZYozPTJzOECyPC=>
HSC3  NVnZS5U2S2WubDDWbYFjcWyrdImgRZN{[Xl? NGLKOo8x6oDVNECg{txO MVS0PEBp MnrmTWM2OD1{NT61xtEyNjd6MDFOwG0> M3TMclI2OTl6N{i5
HSC3  Mmf2RZBweHSxc3nzJGF{e2G7 NITBNnUzPSEQvF2= M2O2NlQ5KGh? M1fjTIlv\HWlZYOgZZBweHSxc3nz MX:yOVE6QDd6OR?=
HSC3  MmHRSpVv[3Srb36gRZN{[Xl? M37rXFI2KM7:TR?= M3;xNVQ5KGh? M4f0eIV5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR? M2D6WVI2OTl6N{i5
HSC3  MoDkSpVv[3Srb36gRZN{[Xl? NXHJT41XOjVizszN NFj5U2Q1QCCq M2niV4lvcGmkaYTzJGhUSzNiY3XscEBqdn[jc3nvckBkd22kaX7l[EB4cXSqIFPFWC=> MonRNlUyQTh5OEm=
HSC3  NGDSSpFHfW6ldHnvckBCe3OjeR?= MV2yOUDPxE1? Ml[0O|IhcA>? MV3k[YNz\WG|ZYOgUW1RNTJiYX7kJG1OWC17IIDyc5RmcW6|wrC= MoXpNlUyQTh5OEm=
201T  NWjPNGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPzO|IhcA>? M1zJemROW09? NVG4SmpKUUN3ME20PE43KML3TR?= NYrFWoNVOjVyNUe5OFE>
273T NHnqT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{n4OlczKGh? NUjpRXlxTE2VTx?= MmXoTWM2OD16MD61JOK2VQ>? MUmyOVA2Pzl2MR?=
Hep-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG2fW8{OC93MD:xNFAh|ryP M1fS[VEzNzJ2L{O2M|Q5KGh? NGLndpNFVVOR MkTEbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MX2yOFk6QDV4NB?=
Hep-2 MV\BdI9xfG:|aYOgRZN{[Xl? M1H2W|UxKM7:TR?= Mn;BNE01QCCq NG\BNJFFVVOR NELzTGRqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MlTLNlQ6QTh3NkS=
Hep-2 NY\tRoFkTnWwY4Tpc44hSXO|YYm= M1jTS|UxKM7:TR?= MYiwMVQ5KGh? NF;ORolFVVOR M1nl[pJm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7 MYGyOFk6QDV4NB?=
Hep-2 MnzqSpVv[3Srb36gRZN{[Xl? NGnCe|A2OCEQvF2= NGPNZ5YxNTR6IHi= NVW5[44zTE2VTx?= M{\kOYRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIHjUSXJV NUnMWXVROjR7OUi1OlQ>
SGC-7901 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\HNVAwPTBxMUCwJO69VQ>? MljUNlQwPDhxN{KgbC=> NEf4enJFVVOR MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MlLoNlQ6QTJ7NUi=
MKN-45 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fIfVExNzVyL{GwNEDPxE1? NWfFUpdDOjRxNEivO|IhcA>? NYPoSo5OTE2VTx?= M2X5[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MVOyOFk6Ojl3OB?=
SGC-7901 MXHGeY5kfGmxbjDBd5NigQ>? NHrVWlUyOC93MD:xNFAh|ryP NVnOdlFKPDhiaB?= MUTEUXNQ NGDNOZJld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MnTVNlQ6QTJ7NUi=
MKN-45 NH;OTnZHfW6ldHnvckBCe3OjeR?= MoXnNVAwPTBxMUCwJO69VQ>? MXW0PEBp NGTEVGxFVVOR NV25Tmpn\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NFraZnIzPDl7Mkm1PC=>
C666-1 NEjneXFEgXSxdH;4bYNqfHliQYPzZZk> NUTzSmNUOjBvOECg{txO MXmyOEBp MlLr[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> NGT3dGQzPDh3NEizPC=>
CNE-1 M4rIWGN6fG:2b4jpZ4l1gSCDc4PhfS=> NWjSRo9XOjBvOECg{txO NV30[HJzOjRiaB?= NVjOeo9N\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? MlnTNlQ5PTR6M{i=
CNE-2 NUL2TVZNS3m2b4TvfIlkcXS7IFHzd4F6 MWOyNE05OCEQvF2= M4i3VlI1KGh? MoO5[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> NWjiVVltOjR6NUS4N|g>
C666-1 NELzOo5EgXSxdH;4bYNqfHliQYPzZZk> NF\2Z4o3OCEQvF2= MWK3JIQ> NILNcG5mdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=> M2G5d|I1QDV2OEO4
CNE-1 MXHDfZRwfG:6aXPpeJkhSXO|YYm= NWPrcldUPjBizszN M4jCU|ch\A>? NITyZYNmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=> MoK3NlQ5PTR6M{i=
SNU-1041 M3vkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfqSnYxNTRyIN88US=> MX:0PEBp NWL3RlVKcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MnfINlQ3QTJ5MEO=
SNU-1041 M1juSWZ2dmO2aX;uJGF{e2G7 MlfINlAwOzBizszN MmXiOEBp MV3pcoR2[2W|IHX4dJJme3Orb36gc4bDqEOKT2CsJGdTWDd6wrDhcoTDqFiEUEJCpIF1KHSqZTDSUmEhdGW4ZX|CpC=> NIXNVIgzPDZ7MkewNy=>
SNU-1041 NUjPfYpMTnWwY4Tpc44hSXO|YYm= M1nJblAuPDBizszN M2PrNlQhcA>? NIribVl2eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?= NV\pelJDOjR4OUK3NFM>
SGC-7901 NVvafHA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTjUGk2OC1zMkWg{txO M3\DZlI1NzR6L{eyJIg> Mm\5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXfPUXB4OjR4N{[zPVQ>
SGC-7901 Mlr6RZBweHSxc3nzJGF{e2G7 NULNVmhpOTByIN88US=> NXLHcI9nPzJiaB?= NXvSbWtQcW6mdXPld{BieG:ydH;zbZM> MWKyOFY4PjN7NB?=
SGC-7901 MYjGeY5kfGmxbjDBd5NigQ>? NEPFS|c4PS9zMECvNVI2KM7:TR?= MXiyOE81QC95MjDo NUPhWnpTcW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI> M3W5WFI1Pjd4M{m0
LMeC  NVfkZ5FpTnWwY4Tpc44hSXO|YYm= NUThV|hROjBxNUCg{txO NIHOS5U1QCCq Mo\E[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IIDyc5RmcW5? Mmm3NlQ3PTZ5NE[=
CMeC-1 M1nkTGNmdGxiVnnhZoltcXS7IFHzd4F6 NFG4[YczOC93MDFOwG0> NFqwdoc1QCCq M3eySolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NGrpdpUzPDZ3Nke0Oi=>
LMeC MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkO2NlAwPTBizszN M{HObVQ5KGh? NIHIdo1qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M{XjS|I1PjV4N{S2
CMeC-1 NHvpRVdHfW6ldHnvckBCe3OjeR?= NYf3T5E5OjBxNUCg{txO NFT1Nlc1QCCq NF3NcZBqdmS3Y3XzJGcyNVNiYYLy[ZN1 NHu4[4czPDZ3Nke0Oi=>
LMeC M1HEXWZ2dmO2aX;uJGF{e2G7 NFzLV|QzOC93MDFOwG0> NUDhN|RTPDhiaB?= NID0eYVqdmS3Y3XzJGcyNVNiYYLy[ZN1 M4HQUVI1PjV4N{S2
CMeC-1 M37jfmZ2dmO2aX;uJGF{e2G7 M1fL[VIxNzVyIN88US=> MUG0PEBp NV;vbFdZ\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXeyOFY2Pjd2Nh?=
LMeC NE\RenVHfW6ldHnvckBCe3OjeR?= M330SFIxNzVyIN88US=> MojSOFghcA>? NYPEbo12\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUeyOFY2Pjd2Nh?=
CMeC-1 Mn;VSpVv[3Srb36gRZN{[Xl? M2TqVVIxNzVyIN88US=> NGXp[lQ1QCCq NFewZo5qdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MormNlQ3PTZ5NE[=
LMeC MYfGeY5kfGmxbjDBd5NigQ>? MnHaNlAwPTBizszN NV;LUo5jPDhiaB?= MX3pcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u MnHGNlQ3PTZ5NE[=
OVCAR-3 MnnFR4VtdCCYaXHibYxqfHliQYPzZZk> NIXz[okyOCEEtV2= NWLmVHJbOSCq MkXm[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> M{G2[|I1PTJyMkK3
OVCAR-3 MljaRZBweHSxc3nzJGF{e2G7 MnvZNVAhyrWP MoDSNUBp MYrwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA> NXfiVXM5OjR3MkCyNlc>
OVCAR-3 MYHGeY5kfGmxbjDBd5NigQ>? M{nI[|ExKML3TR?= M2LXWVEhcA>? NHHqN|dmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDjZZNx[XOnLUpCpC=> MVeyOFUzODJ{Nx?=
OVCAR-3 NUS0VZJQTnWwY4Tpc44hSXO|YYm= NGHx[GUyOCEEtV2= MXmxJIg> MoXh[I94di2{ZXf1cIF1\XNiTl[t{tpDKGGldHn2ZZRqd25iaX7keYNm\CCkeTDwZYNtcXSjeHXs MVSyOFUzODJ{Nx?=
OVCAR-3 NECyemRHfW6ldHnvckBCe3OjeR?= NF\6bYkyOCEEtV2= NUTOWox2OSCq NX3u[GxOcW6qaXLpeJMheGGlbHn0ZZhmdC2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25? NYjpSZM1OjR3MkCyNlc>
CF33 NF20SGZHfW6ldHnvckBCe3OjeR?= NEX1eXgyODBizszN NYPpN2l7OjRiaB?= NFnRXGZqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= NUHLcIluOjR3MEO3PFI>
CF33 NIjiOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fvZ|ExNTFyMDFOwG0> NUHBcoYyOC12IHS= MmC4bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUeyOFUxOzd6Mh?=
CF33 NYD0UoxpTnWwY4Tpc44hSXO|YYm= Ml;NNVAuOTByIN88US=> NH;wfZg1NTJ2IHi= NU\2VlYz\GWlcnXhd4V{KGOnbHzzJIlvKHSqZTDTJJBp[XOnIHHu[EBqdmO{ZXHz[ZMh[2WubIOgbY4hTzBxR{GgZZJz\XO2 NXi5U2hQOjR3MEO3PFI>
LNCaP M3rLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjmXVczNzVxMUCg{txO MlvWPVYhcA>? NUPTZXNYcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> NUW4cYJyOjR{OU[5O|g>
LNCaP NH3UWGZCeG:ydH;zbZMhSXO|YYm= M2T6SVIwPS9zMDFOwG0> NVu3R|FiQTZiaB?= MYXpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?= NFXrb2YzPDJ7Nkm3PC=>
PC-3  MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K5R|AuPTBizszN NYjjOHhyPDkkgJno NUPWbVdrcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NH7GVG0zPDF{N{i4Ni=>
PC-3  Mnu2R4VtdCCYaXHibYxqfHliQYPzZZk> NGHzV5MxNTFyMDFOwG0> NIPMUZc4OiCq NXuwUFVN\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NEDoO4YzPDF{N{i4Ni=>

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03599453 Not yet recruiting Triple -Negative Breast Cancer|Estrogen Receptor Negative|HER2/Neu Negative|Anatomic Stage IV Breast Cancer AJCC|Progesterone Receptor Negative Roswell Park Cancer Institute December 1 2018 Phase 2
NCT03590821 Recruiting Healthy University of Pennsylvania November 1 2018 Early Phase 1
NCT03710876 Not yet recruiting Malignant Pleural Mesothelioma Trizell Ltd|University of Pennsylvania November 2018 Phase 3
NCT01344200 Not yet recruiting Pharmacokinetics of Celecoxib in Children Children''s Hospital of Eastern Ontario November 2018 Phase 4
NCT03694873 Not yet recruiting Perineal Pain Cairo University October 10 2018 Phase 4
NCT03699293 Recruiting Rheumatoid Arthritis|Cardiovascular Diseases Inova Health Care Services September 22 2018 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products4

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID